Literature DB >> 11518707

Capture of a dimeric intermediate during transthyretin amyloid formation.

A Olofsson1, H J Ippel, V Baranov, P Hörstedt, S Wijmenga, E Lundgren.   

Abstract

Point mutations in the human plasma protein transthyretin are associated with the neurological disorder familial amyloidosis with polyneuropathy type 1. The disease is characterized by amyloid fibril deposits causing damage at the site of deposition. Substitution of two amino acids in the hydrophobic core of transthyretin lead to a mutant that was very prone to form amyloid. In addition, this mutant has also been shown to induce a toxic response on a neuroblastoma cell line. Renaturation of the transthyretin mutant at low temperature facilitated the isolation of an amyloid-forming intermediate state having the apparent size of a dimer. Increasing the temperature effectively enhanced the rate of interconversion from a partly denatured protein to mature amyloid. Using circular dichroism the beta-sheet content of the formed mature fibrils was significantly lower than that of the native fold of transthyretin. Morphology studies using electron microscopy also indicated a temperature-dependent transformation from amorphous aggregates toward mature amyloid fibrils. In addition, 1-anilino-8-naphtalenesulfonate fluorescence studies suggested the loss of the thyroxin-binding channel within both the isolated intermediate and the mature fibrils.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518707     DOI: 10.1074/jbc.M103599200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein.

Authors:  Fredrik Noborn; Paul O'Callaghan; Erik Hermansson; Xiao Zhang; John B Ancsin; Ana M Damas; Ingrid Dacklin; Jenny Presto; Jan Johansson; Maria J Saraiva; Erik Lundgren; Robert Kisilevsky; Per Westermark; Jin-Ping Li
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

2.  Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.

Authors:  Luís Gales; Sandra Macedo-Ribeiro; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva; Ana Margarida Damas
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

3.  Alteration of transthyretin microheterogeneity in serum of multiple trauma patients.

Authors:  Beate Gericke; Jens Raila; Maria Deja; Sascha Rohn; Bernd Donaubauer; Britta Nagl; Sophie Haebel; Florian J Schweigert; Udo Kaisers
Journal:  Biomark Insights       Date:  2007-08-08

4.  Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.

Authors:  Mingfeng Yang; Ming Lei; Shuanghong Huo
Journal:  Protein Sci       Date:  2003-06       Impact factor: 6.725

Review 5.  Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.

Authors:  Jin-Beom Si; Bokyung Kim; Jin Hae Kim
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

6.  Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis.

Authors:  Malgorzata Pokrzywa; Ingrid Dacklin; Monika Vestling; Dan Hultmark; Erik Lundgren; Rafael Cantera
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

7.  Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity.

Authors:  Ana Frangolho; Bruno E Correia; Daniela C Vaz; Zaida L Almeida; Rui M M Brito
Journal:  Molecules       Date:  2020-12-03       Impact factor: 4.411

8.  Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.

Authors:  Karin Andersson; Malgorzata Pokrzywa; Ingrid Dacklin; Erik Lundgren
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.